Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00976599 · ClinicalTrials.gov registry record · Phase 2
A Study To Evaluate The Mechanism Of Action Of CP-690,550 In Patients With Rheumatoid Arthritis
A Phase 2 study of Rheumatoid Arthritis, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 29
- Enrollment target
- 15
- Study locations
NCT00976599: Completed Phase 2 study of Rheumatoid Arthritis, sponsored by Pfizer.
NCT00976599 is a Phase 2 study of Rheumatoid Arthritis that has completed, run by Pfizer. The registered enrollment target is 29 participants, below the 4,690-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (99% lower). The trial reports 15 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00976599, a Phase 2 study of Rheumatoid Arthritis, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 29 participants
- Enrollment target
- 15
- Study locations
Study Summary
To explore the effect of CP-690,550 on blood and synovial markers in subjects with rheumatoid arthritis. To evaluate the safety, tolerability and efficacy of CP-690,550.
Primary Outcome
Synovial tissue biopsy were performed and assayed for mRNA gene expression by quantitative polymerized chain reaction (PCR) using standard curve method. Standard curve generated by linear regression using log threshold cycle versus log (cell number). Interleukin-1beta (IL-1beta), IL-6, matrix metalloproteinase-3 (MMP3), cluster of differentiation 19 (CD19), cluster of differentiation 3 epsilon (CD3E), Janus kinase 1 (JAK1), JAK2, JAK3, signal transducers, activators of transcription (STAT1), int
Conditions Studied
Interventions
- DRUG CP-690,550 + methotrexate
- DRUG Placebo + Methotrexate
Study Locations (15)
Texas
- Pfizer Investigational Site - Dallas
- Pfizer Investigational Site - Dallas
- Pfizer Investigational Site - Mesquite
- Pfizer Investigational Site - Sunnyvale
Alabama
- Pfizer Investigational Site - Birmingham
- Pfizer Investigational Site - Birmingham
- Pfizer Investigational Site - Birmingham
Ohio
- Pfizer Investigational Site - Mayfield Village
- Pfizer Investigational Site - Mentor
- Pfizer Investigational Site - Willoughby
Washington
- Pfizer Investigational Site - Seattle
- Pfizer Investigational Site - Seattle
California
- Pfizer Investigational Site - La Jolla
Maryland
- Pfizer Investigational Site - Frederick
Michigan
- Pfizer Investigational Site - Battle Creek
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2009-11 |
| Est. Completion | 2011-07 |
| Phase | Phase 2 |
What the finished NCT00976599 record still lists
NCT00976599 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 29 participants, a relatively small participant target, below the 4,690-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Rheumatoid Arthritis appearing as the primary indexed condition, and to 2 interventions - of which CP-690,550 + methotrexate is the first listed.
NCT00976599 lists 15 locations in 7 states (Texas, Alabama, Ohio).
Frequently Asked Questions
What is clinical trial NCT00976599 about?
NCT00976599 is a clinical study titled "A Study To Evaluate The Mechanism Of Action Of CP-690,550 In Patients With Rheumatoid Arthritis". To explore the effect of CP-690,550 on blood and synovial markers in subjects with rheumatoid arthritis. To evaluate the safety, tolerability and efficacy of CP-690,550.
What is the current status of trial NCT00976599?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 2009-11. Estimated completion is 2011-07.
What conditions does trial NCT00976599 study?
This clinical trial studies the following conditions: Rheumatoid Arthritis.
What interventions are being tested in trial NCT00976599?
The interventions under investigation include: CP-690,550 + methotrexate (DRUG), Placebo + Methotrexate (DRUG).
Who is sponsoring clinical trial NCT00976599?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00976599 being conducted?
This trial has 15 study locations across Alabama, California, Maryland, Michigan, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rheumatoid Arthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00976599's enrollment target sits among peer trials
29 165th of 197 higher than 33 of 197 other Rheumatoid Arthritis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Rheumatoid Arthritis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of SPY072 in Rheumatic Disease
RECRUITING · Phase 2
-
Dynamic Treatment Regiments for Glucocorticoid Tapering
RECRUITING · Phase 2
-
A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis
RECRUITING · Phase 2
-
A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis
RECRUITING · Phase 2
-
A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors)
RECRUITING · Phase 2
-
An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02429557 · 29 participants · Phase 1
Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure
- NCT02568878 · 29 participants · Phase 3
Creatine for Depressed Male and Female Methamphetamine Users
- NCT03014401 · 29 participants · NA
The Effect of Adipose-Derived Stem Cells for Knee Osteoarthritis
- NCT03128996 · 29 participants · Phase 1
Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia